

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Pratt**

Application No: **10/623,577**

Group Art Unit: **1614**

Filed: **July 22, 2003**

Examiner: **R. Cook**

For: **Liquid Dosage Formulations of Donepezil**

Docket: 61368-223339

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicant brings to the attention of the Examiner the documents listed on the attached PTO-1449 Form. A copy of the cited documents is submitted herewith.

The submission of this Information Disclosure Statement does not represent that a search has been made and does not constitute an admission that the listed documents are prior art or material to patentability.

This Information Disclosure Statement is being filed after a first office action on the merits, but prior to a final office action or notice of allowance. Accordingly, the Commissioner is authorized to charge the fee of \$180 to Deposit Account No. 22-0261. The Commissioner is authorized to charge any other necessary fees or credit any overpayments to Deposit Account No. 22-0261.

Applicant respectfully requests that an initialed copy of the PTO-1449 Form be returned with the next communication from the Office.

Respectfully submitted,




Edward D. Grief
Registration No. 38,898
Date: March 23, 2006
Venable LLP
575 7th Street, NW
Washington, DC 20004
Phone: 202-344-4382

03/27/2006 HALI11 00000025 220261 10623577

01 FC:1806 180.00 DA

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/623,577
		Filing Date	July 22, 2003
		First Named Inventor	Pratt
		Art Unit	1614
		Examiner Name	Cook
Sheet 2	of 2	Attorney Docket Number 223339	



NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Mendez et al, J. Neuropsychiatry Clin Neurosci, 11(2):268-270 (1999).	
		Hasegawa et al, Folia Pharmacologica Japonica, 114(6):327-336 (1999).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.